Esperion Therapeutics (ESPR) Amortizatization of Intangibles (2013 - 2023)
Esperion Therapeutics (ESPR) posted Amortizatization of Intangibles of -$100000.0 for Q2 2023, down 129.5% on a QoQ basis from $339000.0 in Q1 2023, and up 50.0% year-over-year from -$66666.7 in Q2 2022.
Esperion Therapeutics (ESPR) Amortizatization of Intangibles (2013 - 2023) Analysis & Trends
Esperion Therapeutics' Amortizatization of Intangibles history runs 11 years deep, the most recent figure standing at -$100000.0 for Q2 2023.
- Quarterly Amortizatization of Intangibles rose 50.0% year-over-year to -$100000.0 in Q2 2023, while the trailing twelve-month figure through Mar 2024 was -$100000.0 (down 150.25% YoY) and the FY2023 annual result came in at $412000.0, up 247.67% from the prior year.
- Amortizatization of Intangibles was -$100000.0 for Q2 2023 at Esperion Therapeutics, down from $339000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $339000.0 in Q1 2023 and bottomed at -$200000.0 in Q3 2019.
- A 5-year average of -$27000.0 and a median of -$100000.0 in 2019 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2019 — Amortizatization of Intangibles plunged 300.0% — and 2022, when it jumped 2266.67%.
- Esperion Therapeutics' Amortizatization of Intangibles stood at $60000.0 in 2019, then slumped by 266.67% to -$100000.0 in 2020, then surged by 88.0% to -$12000.0 in 2021, then soared by 2266.67% to $260000.0 in 2022, then tumbled by 138.46% to -$100000.0 in 2023.
- Business Quant data shows ESPR's Amortizatization of Intangibles at -$100000.0 in Q2 2023, $339000.0 in Q1 2023, and $260000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 1.30 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -100,000.00 |
| Jun 30, 2023 | -100,000.00 |
| Mar 31, 2023 | 339,000.00 |
| Mar 31, 2023 | 339,000.00 |
| Dec 31, 2022 | 260,000.00 |
| Dec 31, 2022 | 260,000.00 |
| Sep 30, 2022 | -200,000.00 |
| Sep 30, 2022 | -200,000.00 |
| Jun 30, 2022 | -200,000.00 |
| Jun 30, 2022 | -200,000.00 |
| Mar 31, 2022 | -173,000.00 |
| Mar 31, 2022 | -173,000.00 |
| Dec 31, 2021 | -12,000.00 |
| Dec 31, 2021 | -12,000.00 |
| Sep 30, 2020 | -100,000.00 |
| Sep 30, 2020 | -100,000.00 |
| Jun 30, 2020 | -100,000.00 |
| Jun 30, 2020 | -100,000.00 |
| Mar 31, 2020 | 73,000.00 |
| Mar 31, 2020 | 73,000.00 |